Both EcoNail and pexiganan are being developed for diseases of the foot predominantly treated by the same prescribing specialists, namely podiatrists. Both products would potentially be of interest to a larger number of physician specialists and primary care physicians as well. EcoNail is the company's patented lacquer which contains the antifungal econazole and MacroChem's enhancer SEPA(R). Patients participating in the EcoNail study will receive forty-eight weeks of treatment and will undergo efficacy assessments using standard criteria of nail appearance and mycology. However, the Company will collect and evaluate twenty-four week interim data. This trial was specifically designed, with the assistance of well-known onychomycosis experts, to address three important objectives: to assess early signs of efficacy, to maintain robust clinical endpoints in the full study, and, if successful, to facilitate advancement to Phase 3 as soon as possible.
MacroChem Corporation is a specialty pharmaceutical company that
develops and seeks to commercialize pharmaceutical products. Our lead
product candidate is EcoNail, a topically applied SEPA-based econazole
lacquer for the treatment of onychomycosis, a condition commonly known as
nail fungus. We recently acquired exclusive worldwide license rights to
pexiganan, a novel topical anti-infective for the treatment of diabetic
foot infection, which has already completed two Phase 3 trials. Our other
clinical stage product candidate, Opterone(R), is a topically applied
SEPA-based testosterone cream designed to treat male hypogonadism. Our
pipeline of clinical-stage and early-stage product candidates is based on
our SEPA, MacroDerm(TM) and DermaPass(TM) drug delivery technologies. For
more information visit our website,
|SOURCE MacroChem Corporation|
Copyright©2007 PR Newswire.
All rights reserved